(redirected from Androgen antagonist)
Also found in: Dictionary.


any steroid hormone that promotes male secondary sex characters. The two main androgens are androsterone and testosterone. Called also androgenic hormone. adj., adj androgen´ic. 

The androgenic hormones are internal endocrine secretions circulating in the bloodstream and manufactured mainly by the testes under stimulation from the pituitary gland. To a lesser extent, androgens are produced by the adrenal glands in both sexes, as well as by the ovaries in women. Thus women normally have a small percentage of male hormones, in the same way that men's bodies contain some female sex hormones, the estrogens. Male secondary sex characters include growth of the beard and deepening of the voice at puberty. Androgens also stimulate the growth of muscle and bones throughout the body and thus account in part for the greater strength and size of men as compared to women.
androgen insensitivity syndrome complete androgen resistance.


Any substance capable of preventing full expression of the biologic effects of androgenic hormones on responsive tissues, either by producing antagonistic effects on the target tissue, as estrogens do, or by merely inhibiting androgenic effects, such as by competing for binding sites at the cell surface.


/an·ti·an·dro·gen/ (-an´dro-jen) any substance capable of inhibiting the biological effects of androgens.


(ăn′tē-ăn′drə-jən, ăn′tī-)
A substance that inhibits the biological effects of androgenic hormones.


Endocrinology A hormone or other agent–eg, megestrol acetate, spironolactone, flutamide, nilutamide, and cimetidine, which interferes with androgen function by competitively inhibiting androgen binding to cognate receptors at the target organ and is either biologically inert or functionally very weak; these compounds are used to manage androgen-dependent CAs–♂ breast and prostate, hirsutism, acne


A substance that blocks the action of androgens, the hormones responsible for male characteristics. Used to treat prostate cancers that require male hormones for growth.
Mentioned in: Prostate Cancer


any substance capable of inhibiting the biological effects of androgenic hormones.
References in periodicals archive ?
Four laboratories assessed the detection of this androgen antagonist using doses of 3, 10, 30, and 100 mg PRO/kg bw/day coadministered with 0.
Four laboratories assessed the detection of this weak androgen antagonist using doses of 3, 10, 30, and 100 mg LIN/kg bw/day coadministered with 0.
CONCLUSIONS: The results show that the OECD Hershberger bioassay protocol is reproducible and transferable across laboratories with androgen agonists, weak androgen antagonists, and a 5[alpha]-reductase inhibitor.
Four androgen antagonists and a 5[alpha]-reductase inhibitor were used as test substances.
9% pure), and the reference androgen antagonist (FLU) (CASRN 13311-84-7) was from Salutas Pharma (Barleben, Germany; 99.
Based on this phase 1 validation study, the protocols have been refined, and the next phase of the OECD validation program will test the protocol with selected doses of weak androgen agonists, androgen antagonists, a 5[alpha]-reductase inhibitor, and chemicals having no androgenic activity.
Then, the assay was adapted for androgen antagonists such as flutamide (FLU) (Peets et al.
For the androgen antagonists (VCZ and p,p'-DDE), 0.
This finding demonstrates that no significant differences exist regarding the use of SD and Wistar rats in the Hershberger assay for the detection of androgen antagonists.